A Study of Donanemab in participants with early Alzheimer’s disease (TRAILBLAZER-ALZ 2)

Project Type(s):

Principal Investigator(s):

Project website

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease.

Project Period:
June 18, 2020

Funding Type(s):
Private company/industry

Eli Lilly and Company

Geographic Area(s):
Alaska, Seattle/Puget Sound, University of Washington, Washington

Practice Type(s):

Patient Population(s):

Targeted Condition(s):
Cognitive Disorders